Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
P126394-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $129.90 | |
P126394-25mg | 25mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $585.90 | |
P126394-100mg | 100mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $652.90 |
Potent FAK inhibitor
Synonyms | 2-((2-((2-methoxy-4-morpholinophenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)-N-methylbenzamide. | Q27089163 | SCHEMBL47360 | 2-(2-(2-Methoxy-4-morpholinophenylamino)-5-(trifluoromethyl)pyridine-4-ylamino)-N-methylbenzamide | PND-1186 (VS-4718) | MFC |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | Potent FAK inhibitor (IC50values are 1.5 and 100 nM for recombinant FAK and FAK in breast carcinoma cells, respectively). Promotes caspase activation; triggering apoptosis. Inhibits 4T1 breast carcinoma subcutaneous tumor growth and breast carcinoma cell |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Focal adhesion kinase 1 inhibitor |
Note | 卖完停产,不再备货 |
Product Description | PND-1186 is a potent FAK inhibitor with IC50 of 1.5 nM. |
ALogP | 4.7 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 2-[[2-(2-methoxy-4-morpholin-4-ylanilino)-5-(trifluoromethyl)pyridin-4-yl]amino]-N-methylbenzamide |
---|---|
INCHI | InChI=1S/C25H26F3N5O3/c1-29-24(34)17-5-3-4-6-19(17)31-21-14-23(30-15-18(21)25(26,27)28)32-20-8-7-16(13-22(20)35-2)33-9-11-36-12-10-33/h3-8,13-15H,9-12H2,1-2H3,(H,29,34)(H2,30,31,32) |
InChi Key | IGUBBWJDMLCRIK-UHFFFAOYSA-N |
Canonical SMILES | CNC(=O)C1=CC=CC=C1NC2=CC(=NC=C2C(F)(F)F)NC3=C(C=C(C=C3)N4CCOCC4)OC |
Isomeric SMILES | CNC(=O)C1=CC=CC=C1NC2=CC(=NC=C2C(F)(F)F)NC3=C(C=C(C=C3)N4CCOCC4)OC |
PubChem CID | 25073775 |
Molecular Weight | 501.5 |
PubChem CID | 25073775 |
---|---|
ChEMBL Ligand | CHEMBL3040440 |
CAS Registry No. | 1061353-68-1 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
F1702060 | Certificate of Analysis | Jan 19, 2023 | P126394 |
Solubility | Solvent:DMSO, Max Conc. mg/mL: 50.15, Max Conc. mM: 100 |
---|
1. Tanjoni I, Walsh C, Uryu S, Tomar A, Nam JO, Mielgo A, Lim ST, Liang C, Koenig M, Sun C et al.. (2010) PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments.. Cancer Biol Ther, 9 (10): (764-77). [PMID:20234191] [10.1021/op500134e] |
2. Tancioni I, Uryu S, Sulzmaier FJ, Shah NR, Lawson C, Miller NL, Jean C, Chen XL, Ward KK, Schlaepfer DD. (2014) FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.. Mol Cancer Ther, 13 (8): (2050-61). [PMID:24899686] [10.1021/op500134e] |
3. Lee BY, Timpson P, Horvath LG, Daly RJ. (2015) FAK signaling in human cancer as a target for therapeutics.. Pharmacol Ther, 146 (13): (132-49). [PMID:25316657] [10.1021/op500134e] |